RPL19P18

Across TCGA pan-cancer cohorts, RPL19P18 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RPL19P18’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RPL19P18 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL19P18 is over-expressed in tumor, although a few such as LUSC show the opposite, repressed pattern.

HNSC, BRCA, and LUSC are the cancer types where RPL19P18 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL19P18 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	+0.020	.034	3	view →
BRCA	Female	II,III,IV	+0.017	.043	2	view →
LUSC	Female	All	−0.071	.041	1	view →
STAD	Male	All	+0.058	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RPL19P18–HNSC

Open the HNSC breakdown →